215 related articles for article (PubMed ID: 11864629)
1. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
[TBL] [Abstract][Full Text] [Related]
2. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
3. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.
Denovan-Wright EM; Robertson HA
Neuroscience; 2000; 98(4):705-13. PubMed ID: 10891614
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
[TBL] [Abstract][Full Text] [Related]
6. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I; Cebeira M; de Ceballos ML; Zeng BY; Jenner P; Ramos JA; Fernández-Ruiz JJ
Eur J Neurosci; 2001 Dec; 14(11):1827-32. PubMed ID: 11860478
[TBL] [Abstract][Full Text] [Related]
7. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
8. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats.
Romero J; Berrendero F; Garcia-Gil L; de la Cruz P; Ramos JA; Fernández-Ruiz JJ
Neuroscience; 1998 Jun; 84(4):1075-83. PubMed ID: 9578396
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
10. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia.
Page KJ; Besret L; Jain M; Monaghan EM; Dunnett SB; Everitt BJ
Exp Brain Res; 2000 Jan; 130(2):142-50. PubMed ID: 10672467
[TBL] [Abstract][Full Text] [Related]
11. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
Lastres-Becker I; Fezza F; Cebeira M; Bisogno T; Ramos JA; Milone A; Fernández-Ruiz J; Di Marzo V
Neuroreport; 2001 Jul; 12(10):2125-9. PubMed ID: 11447320
[TBL] [Abstract][Full Text] [Related]
12. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen.
Romero J; Berrendero F; Pérez-Rosado A; Manzanares J; Rojo A; Fernández-Ruiz JJ; de Yebenes JG; Ramos JA
Life Sci; 2000; 66(6):485-94. PubMed ID: 10794065
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide.
Romero J; Berrendero F; García-Gil L; Lin SY; Makriyannis A; Ramos JA; Fernández-Ruiz JJ
Neurochem Int; 1999 Jun; 34(6):473-82. PubMed ID: 10402222
[TBL] [Abstract][Full Text] [Related]
14. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia.
Julian MD; Martin AB; Cuellar B; Rodriguez De Fonseca F; Navarro M; Moratalla R; Garcia-Segura LM
Neuroscience; 2003; 119(1):309-18. PubMed ID: 12763090
[TBL] [Abstract][Full Text] [Related]
15. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.
Glass M; van Dellen A; Blakemore C; Hannan AJ; Faull RL
Neuroscience; 2004; 123(1):207-12. PubMed ID: 14667455
[TBL] [Abstract][Full Text] [Related]
16. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol.
Romero J; Berrendero F; Manzanares J; Pérez A; Corchero J; Fuentes JA; Fernández-Ruiz JJ; Ramos JA
Synapse; 1998 Nov; 30(3):298-308. PubMed ID: 9776133
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
Allen KL; Waldvogel HJ; Glass M; Faull RL
J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
[TBL] [Abstract][Full Text] [Related]
18. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Glass M; Faull RL; Dragunow M
Neuroscience; 1993 Oct; 56(3):523-7. PubMed ID: 8255419
[TBL] [Abstract][Full Text] [Related]
19. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.
Mailleux P; Vanderhaeghen JJ
Neuroscience; 1992; 48(3):655-68. PubMed ID: 1376455
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.
Corchero J; Romero J; Berrendero F; Fernandez-Ruiz J; Ramos JA; Fuentes JA; Manzanares J
Brain Res Mol Brain Res; 1999 Apr; 67(1):148-57. PubMed ID: 10101241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
